HU181725B - Process for producing immunotherapeutic pharmaceutical composition - Google Patents
Process for producing immunotherapeutic pharmaceutical composition Download PDFInfo
- Publication number
- HU181725B HU181725B HU801726A HU172680A HU181725B HU 181725 B HU181725 B HU 181725B HU 801726 A HU801726 A HU 801726A HU 172680 A HU172680 A HU 172680A HU 181725 B HU181725 B HU 181725B
- Authority
- HU
- Hungary
- Prior art keywords
- nctc
- strains
- lysate
- cultured
- sodium
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 230000001024 immunotherapeutic effect Effects 0.000 title description 2
- 239000006166 lysate Substances 0.000 claims abstract description 22
- 239000007788 liquid Substances 0.000 claims abstract description 8
- 239000007787 solid Substances 0.000 claims abstract description 5
- 241000894006 Bacteria Species 0.000 claims abstract description 4
- 241000588724 Escherichia coli Species 0.000 claims abstract description 4
- 239000004480 active ingredient Substances 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 8
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 235000013372 meat Nutrition 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 239000004251 Ammonium lactate Substances 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 239000008156 Ringer's lactate solution Substances 0.000 claims description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 2
- 229940059265 ammonium lactate Drugs 0.000 claims description 2
- 235000019286 ammonium lactate Nutrition 0.000 claims description 2
- RZOBLYBZQXQGFY-HSHFZTNMSA-N azanium;(2r)-2-hydroxypropanoate Chemical compound [NH4+].C[C@@H](O)C([O-])=O RZOBLYBZQXQGFY-HSHFZTNMSA-N 0.000 claims description 2
- 229940041514 candida albicans extract Drugs 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000001968 nicotinic acid Nutrition 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- 239000011664 nicotinic acid Substances 0.000 claims description 2
- 239000001632 sodium acetate Substances 0.000 claims description 2
- 235000017281 sodium acetate Nutrition 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 2
- 235000019157 thiamine Nutrition 0.000 claims description 2
- 239000011721 thiamine Substances 0.000 claims description 2
- 210000001635 urinary tract Anatomy 0.000 claims description 2
- 239000012138 yeast extract Substances 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- -1 sodium monohydrogen Chemical class 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 5
- 230000001580 bacterial effect Effects 0.000 abstract description 2
- 208000019206 urinary tract infection Diseases 0.000 abstract description 2
- 206010022678 Intestinal infections Diseases 0.000 abstract 1
- 239000007640 basal medium Substances 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 206010057249 Phagocytosis Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002934 lysing effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH692479A CH639852A5 (fr) | 1979-07-26 | 1979-07-26 | Medicament contre les maladies infectieuses des voies urinaires et digestives. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HU181725B true HU181725B (en) | 1983-11-28 |
Family
ID=4317195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU801726A HU181725B (en) | 1979-07-26 | 1980-07-10 | Process for producing immunotherapeutic pharmaceutical composition |
Country Status (16)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2550707B1 (fr) * | 1983-08-17 | 1986-02-28 | Lipha | Medicament immunomodulateur d'origine biologique et son procede de preparation |
| US4740585A (en) * | 1984-07-30 | 1988-04-26 | The Board Of Trustees Of The Leland Stanford Junior University | Synthetic vaccine against urinary infections |
| EP2345421A1 (en) | 2003-06-23 | 2011-07-20 | Biotech Tools S.A. | Epitope composition for sublingual or enteric administration prepared by hydrolysis of antigenic structures with chymotrypsin |
| AU2008222863B2 (en) * | 2007-03-05 | 2012-11-08 | Om Pharma | Bacterial extract for digestive or urinary tract disorders and process for its preparation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1336015A (en) * | 1970-06-03 | 1973-11-07 | Unilever Ltd | Rearing pigs |
| US3911109A (en) * | 1971-10-14 | 1975-10-07 | Lever Brothers Ltd | Rearing calves |
| BE789864A (fr) * | 1971-10-14 | 1973-04-09 | Unilever Nv | Elevage des veaux |
| JPS5219927B2 (enrdf_load_html_response) * | 1972-06-08 | 1977-05-31 | ||
| GB1462384A (en) * | 1973-04-12 | 1977-01-26 | Unilever Ltd | Rearing of lambs |
| US4141970A (en) * | 1975-05-07 | 1979-02-27 | Internationale Octrooimaatschappij "Octropa" B.V. | Method for enhancing the resistance of new born mammalian young to gastro-intestinal infections |
| GB1560934A (en) * | 1975-05-07 | 1980-02-13 | Unilever Ltd | Methods for the resistance of non-human mammals to gastro-intestinal disorders |
| US4136167A (en) * | 1975-06-12 | 1979-01-23 | Internationale Octrooi Maatschappij "Octropa" B.V. | Process for reducing the incidence of neonatal diarrhoea in pigs |
| GB1581776A (en) * | 1976-08-18 | 1980-12-17 | Smith Kline Rit | Vaccines against oedema disease of piglets |
-
1979
- 1979-07-26 CH CH692479A patent/CH639852A5/fr not_active IP Right Cessation
-
1980
- 1980-05-21 DE DE19803019448 patent/DE3019448A1/de active Granted
- 1980-05-28 ES ES491920A patent/ES8104402A1/es not_active Expired
- 1980-06-06 FR FR8012677A patent/FR2462164A1/fr active Granted
- 1980-07-10 HU HU801726A patent/HU181725B/hu unknown
- 1980-07-14 DD DD222593A patent/DD153192A5/de not_active IP Right Cessation
- 1980-07-22 RO RO80101780A patent/RO80054A/ro unknown
- 1980-07-24 IT IT49314/80A patent/IT1143025B/it active
- 1980-07-24 BE BE0/201514A patent/BE884456A/fr not_active IP Right Cessation
- 1980-07-24 PL PL1980225853A patent/PL127520B1/pl unknown
- 1980-07-25 JP JP10231580A patent/JPS5622733A/ja active Granted
- 1980-07-25 CS CS805266A patent/CS212234B2/cs unknown
- 1980-07-25 PT PT71612A patent/PT71612A/pt unknown
- 1980-07-25 AR AR281940A patent/AR222887A1/es active
- 1980-07-25 GB GB8024420A patent/GB2054374B/en not_active Expired
- 1980-07-25 YU YU1896/80A patent/YU42532B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DD153192A5 (de) | 1981-12-30 |
| AR222887A1 (es) | 1981-06-30 |
| YU189680A (en) | 1983-06-30 |
| YU42532B (en) | 1988-10-31 |
| JPS5622733A (en) | 1981-03-03 |
| CH639852A5 (fr) | 1983-12-15 |
| IT1143025B (it) | 1986-10-22 |
| GB2054374B (en) | 1983-06-22 |
| CS212234B2 (en) | 1982-03-26 |
| PT71612A (fr) | 1980-08-01 |
| DE3019448A1 (de) | 1981-02-12 |
| IT8049314A0 (it) | 1980-07-24 |
| ES491920A0 (es) | 1981-04-01 |
| FR2462164A1 (fr) | 1981-02-13 |
| DE3019448C2 (enrdf_load_html_response) | 1987-07-30 |
| RO80054A (ro) | 1982-10-26 |
| BE884456A (fr) | 1980-11-17 |
| ES8104402A1 (es) | 1981-04-01 |
| GB2054374A (en) | 1981-02-18 |
| PL225853A1 (enrdf_load_html_response) | 1981-05-08 |
| JPH0255407B2 (enrdf_load_html_response) | 1990-11-27 |
| PL127520B1 (en) | 1983-11-30 |
| FR2462164B1 (enrdf_load_html_response) | 1983-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1246445A (en) | Intestinal microflora-improving agent | |
| JP3653277B2 (ja) | ラクトバチルス菌株、該菌株の組成物および該菌株の使用法 | |
| EP0555618B1 (en) | Dietetic and/or pharmaceutical compositions containing lyophilized lactic bacteria | |
| CN117143783B (zh) | 一种唾液联合乳杆菌vb330及其应用 | |
| CH653556A5 (de) | Arzneimittel mit antitumor-wirkung. | |
| TW202034776A (zh) | 長雙歧桿菌長亞種、含其的組合物及用途 | |
| CN114774315A (zh) | 鼠李糖乳杆菌菌株LRa05在制备增强免疫力制品和/或缓解湿疹制品方面的用途 | |
| US20130309212A1 (en) | Lactobacillus salivarius and method for preparing metabolite thereof, composition of lactobacillus salivarius and metabolite thereof and use of the composition | |
| WO2019051790A1 (zh) | 单形巨单胞菌(Megamonas funiformis)及其应用 | |
| JPH0696538B2 (ja) | 抗発癌剤 | |
| CN117106679A (zh) | 一种缓解胰岛素抵抗的益生菌剂及其应用 | |
| US4451457A (en) | Cyclodextrin and method for promoting the proliferation of intestinal bifidobacteria | |
| TWI754929B (zh) | 乳酸菌用於提升對腸病毒７１型之抵抗力之用途 | |
| US4343784A (en) | Composition and method employing extracts of Hansenula as a medicament | |
| HU181725B (en) | Process for producing immunotherapeutic pharmaceutical composition | |
| WO2019109348A1 (zh) | 丁酸杆菌(Butyribacter intestini)在预防和/或治疗炎症相关疾病的应用 | |
| KR102792146B1 (ko) | 건강한 한국인 여성 질 유래 락티플란티바실러스 플란타룸 균주 및 이를 포함하는 조성물 | |
| KR0169982B1 (ko) | 피부염 치료용 약제 | |
| CN107929329B (zh) | 一种消栓降脂益生复合菌中药颗粒及其制备方法 | |
| JPS61271223A (ja) | 血中脂質改善剤 | |
| JP2969017B2 (ja) | 感染防御剤 | |
| WO2018107364A1 (zh) | 深圳柯林斯菌(Collinsella shenzhenensis)及其应用 | |
| EP0196858B1 (en) | Liver function-improving agent and blood pressure-lowering agent | |
| EP0396744A1 (en) | Lipid peroxide content reducer | |
| JPS6069022A (ja) | 免疫調整剤及びその製造法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HU90 | Patent valid on 900628 |